Skip to content

Study · Case report or series · n = 1 · 2026

3 results

Can semaglutide influence tumor biomarkers? Insight from a clinical case.

Schianchi A, Mauri F, Polli C

Journal of food and drug analysis1 Jun 2026

PMID42485519 (opens in a new tab)PMCIDPMC13391009 (opens in a new tab)DOI10.38212/2224-6614.3594 (opens in a new tab)PepBankPUB-42485519
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 61-year-old patient on semaglutide, tumor biomarker testing showed a significant increase in CA 19-9, and all further investigations were normal.

    In plain wordsOne 61-year-old patient on semaglutide had a high CA 19-9 tumor marker with no disease found. A link to semaglutide is not shown.

    Peptide
    Semaglutide
    Outcome
    IncreaseCA 19-9 level
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tumor biomarker testing revealed a significant increase in CA 19-9 and a mild elevation in CA-125.
    2 context sentences
    Summary · context
    The patient was on Semaglutide treatment.
    Summary · context
    However, all further investigations yielded normal results.
  2. 02HumanCase report or seriesSafety outcome

    In a 61-year-old patient on semaglutide, tumor biomarker testing showed a mild elevation in CA-125, and all further investigations were normal.

    In plain wordsOne 61-year-old patient on semaglutide had a mildly high CA-125 tumor marker with no disease found. A link to semaglutide is not shown.

    Peptide
    Semaglutide
    Outcome
    IncreaseCA-125 level
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tumor biomarker testing revealed a significant increase in CA 19-9 and a mild elevation in CA-125.
    2 context sentences
    Summary · context
    The patient was on Semaglutide treatment.
    Summary · context
    However, all further investigations yielded normal results.
  3. 03HumanCase report or seriesSafety outcome

    In a 61-year-old patient who had been on semaglutide, CA 19-9 fell from 717 to 62 kU/L one month later and tumor biomarkers were normal after two months.

    In plain wordsIn one patient, the raised CA 19-9 level dropped within a month and was normal after two months.

    Peptide
    Semaglutide
    Outcome
    DecreaseCA 19-9 level at one-month follow-up
    Study

    n = 1

    Outcome group
    Adverse events · Cancer
    Studied dose
    Dose not stated

    Measurements

    CA 19-9
    717 kU/L
    initial
    CA 19-9
    62 kU/L
    one-month follow-up

    Source sentences

    Summary
    At a follow-up laboratory check one month later, CA 19-9 levels had decreased from 717 to 62 kU/L.
    2 context sentences
    Summary · context
    A subsequent evaluation two months later confirmed the normalization of tumor biomarkers.
    Summary · context
    The patient was on Semaglutide treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.